Abstract
Purpose
To evaluate whether initiation of a fibrate or statin increases the risk of hospitalization
for gastrointestinal bleeding in warfarin users.
Methods
We used Medicaid claims data (1999-2003) to perform an observational case-control
study nested within person-time exposed to warfarin in those ≥18 years (n=353,489). Gastrointestinal bleeding cases were matched to 50 controls based on index
date and state.
Results
Chronic warfarin users had an increased odds ratio of gastrointestinal bleeding upon
initiation of gemfibrozil (1.88; 95% confidence interval [CI], 1.00-3.54] for the
first prescription; 1.75; 95% CI, 0.77-3.95 for the second prescription); simvastatin
(1.46; 95% CI, 1.03-2.07 for the first prescription; 1.60; 95% CI, 1.07-2.39 for the
second prescription); or atorvastatin (1.39; 95% CI, 1.07-1.81 for the first prescription;
1.05; 95% CI, 0.73-1.52 for the second prescription). In contrast, no increased risk
was found with pravastatin initiation (0.75; 95% CI, 0.39-1.46 for the first prescription;
0.90; 95% CI, 0.43-1.91 for the second prescription).
Conclusions
Initiation of a fibrate or statin that inhibits CYP3A4 enzymes, including atorvastatin,
was associated with an increased risk of hospitalization for gastrointestinal bleeding.
Initiation of pravastatin, which is mainly excreted unchanged, was not associated
with an increased risk.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to The American Journal of MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action.Arch Intern Med. 2007; 167: 1414-1419
- Systematic overview of warfarin and its drug and food interactions.Arch Intern Med. 2005; 165: 1095-1106
- Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding.Arch Intern Med. 2006; 166: 853-859
- Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport.Pharm Res. 2006; 23: 506-512
- Frequency of concurrent use of warfarin with potentially interacting drugs.Pharmacotherapy. 2004; 24: 1668-1674
- The effect of simvastatin co-medication on warfarin anticoagulation response and dose requirements.Thromb Haemost. 2003; 89: 949-950
- (Accessed August 10, 2007)
- Drug Facts & Comparisons 4.0.(Accessed July 7, 2007)
- Clinical pharmacokinetics of fibric acid derivatives (fibrates).Clin Pharmacokinet. 1998; 34: 155-162
- Atorvastatin does not alter the anticoagulant activity of warfarin.J Clin Pharmacol. 1997; 37: 1062-1064
- Genetic polymorphisms in assessing interindividual variability in delivered dose.Regul Toxicol Pharmacol. 2002; 35: 177-197
- Gemfibrozil interaction with warfarin sodium (coumadin).Chest. 1990; 98: 1041-1042
- Potential interaction between warfarin and fluvastatin.Ann Pharmacother. 1996; 30: 1399-1402
- Potential warfarin-fluvastatin interaction.Ann Pharmacother. 1997; 31: 790
- Gemfibrozil-warfarin drug interaction resulting in profound hypoprothrombinemia.Chest. 1998; 114: 641-642
- Oral anticoagulant drug interactions with statins: case report of fluvastatin and review of the literature.Pharmacotherapy. 2004; 24: 285-290
- Trends in statin use and low-density lipoprotein cholesterol levels among US adults: impact of the 2001 National Cholesterol Education Program guidelines.Ann Pharmacother. 2008; 42: 1208-1215
- Medicaid databases.in: Strom B.L. Pharmacoepidemiology. 4th edn. John Wiley and Sons, Inc, Chichester, UK2005: 281-294
- Report to the Congress: New Approaches in Medicare.Medicare Payment Advisory Commission, Washington, DC2004
- Quality of Medicaid and Medicare data obtained through Centers for Medicare and Medicaid Services (CMS).Med Care. 2007; 45: 1216-1220
- Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy.Chest. 2005; 127: 1515-1522
- Validity of pharmacoepidemiologic drug and diagnosis data.in: Strom B.L. Pharmacoepidemiology. 4th edn. John Wiley and Sons, Inc, Chichester, UK2005: 709-766
- The exposure odds ratio in nested case-control studies with competing risks.Am J Epidemiol. 1986; 124: 684-692
- The depletion of susceptibles effect in the assessment of burden-of-illness: the example of age-related macular degeneration in the community-dwelling elderly population of Quebec.Can J Clin Pharmacol. 2008; 15: e22-e35
- The impact of confounder selection criteria on effect estimation.Am J Epidemiol. 1989; 129: 125-137
- Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors.Am J Cardiol. 2004; 94: 1140-1146
- Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance.Clin Pharmacol Ther. 2006; 80: 565-581
Article Info
Footnotes
Funding: This project was funded by National Institute on Aging grant R01AG02152 . Apart from suggestions from reviewers during the peer review process, the funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript. Part of the infrastructure for this study was funded by the Clinical and Translational Science Award 5KL2RR024132.
Conflict of Interest: Dr. Schelleman has had travel to scientific conferences paid for by pharmacoepidemiology training funds contributed by pharmaceutical manufacturers. Dr. Bilker has consulted for Johnson & Johnson and Astra Zeneca, unrelated to warfarin, fibrates, and statins. Ms. Brensinger has consulted for a law firm representing Pfizer, unrelated to warfarin, fibrates, and statins. Dr. Yang has served as a consultant for AstraZeneca and has received grant support from AstraZeneca , Wyeth-Ayerst Laboratories , and GlaxoSmithKline , unrelated to warfarin, fibrates, and statins. Dr. Hennessy has had funding from Pfizer and consulted for a law firm representing Bayer and Pfizer, unrelated to warfarin, fibrates, and statins. Mr. Wan had no potential conflict of interest to declare.
Authorship: All authors had access to the data and a role in writing the manuscript.
Identification
Copyright
© 2010 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
